Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Operating Expenses | 5,114 | 3,289 | 4,098 | 5,310 | 5,123 |
| Operating Income | -5,114 | -3,289 | -4,098 | -5,310 | -5,123 |
| Interest Expense | 5 | 10 | 17 | 17 | 8 |
| Other Income | -72 | -28 | 27 | 28 | 789 |
| Pre-tax Income | -5,191 | -3,327 | -4,088 | -5,300 | -4,342 |
| Net Income Continuous | -5,191 | -3,327 | -4,088 | -5,300 | -4,342 |
| Net Income | $-5,191 | $-3,327 | $-4,088 | $-5,300 | $-4,342 |
| EPS Basic Total Ops | -680.23 | -598.04 | 320,135.70 | -44,780.94 | -131,624.90 |
| EPS Basic Continuous Ops | -680.23 | -598.01 | 320,128.20 | -44,780.91 | -131,622.40 |
| EPS Diluted Total Ops | -680.23 | -598.04 | 320,135.70 | -44,780.94 | -131,624.90 |
| EPS Diluted Continuous Ops | -680.23 | -598.01 | 320,128.20 | -44,780.91 | -131,622.40 |
| EPS Diluted Before Non-Recurring Items | -684.10 | -600.90 | N/A | -62,123.85 | N/A |
| EBITDA(a) | $-4,971 | $-3,147 | $-3,957 | $-5,172 | $-4,985 |